Medical and Pharmaceutical Pulmonx Corporation shares spike on record-breaking Q4 revenue Pulmonx achieved USD$83.8 million in worldwide revenue, reflecting a robust 22 per cent growth over 2023 Joseph MortonFebruary 21, 2025
Medical and Pharmaceutical New Korean cancer tech finds mutations with only a few drops of blood In a clinical trial with blood from 83 patients, the test identified 100 per cent of EGFR gene mutations Joseph MortonFebruary 18, 2025
Medical and Pharmaceutical Early lung cancer diagnosis saves 52-year-old Indian man’s life A persistent cough and breathlessness while climbing stairs prompted him to visit the hospital Rowan DunneFebruary 13, 2025
Medical and Pharmaceutical PEI needs to jump on lung cancer screening bandwagon ASAP, advocate says It is the last Canadian province without a program for catching the disease Rowan DunneFebruary 10, 2025
Medical and Pharmaceutical British scientists develop lung cancer blood test that gives results in 40 minutes This new screening device is the product of a 3-year study from Cranfield University scholars Rowan DunneFebruary 7, 2025
Medical and Pharmaceutical Lipella Pharmaceuticals skyrockets on FDA access approval for mouth disease treatment The stock was up by about 200% during early trading hours Rowan DunneFebruary 6, 2025
Medical and Pharmaceutical Obesity reduces risk of dying from lung cancer by 21%, South Korean study finds The investigators examined data from more than 7,000 patients over an 11-year period to make this determination Rowan DunneJanuary 30, 2025
Medical and Pharmaceutical FDA gives Zai Lab’s small cell lung cancer therapeutic orphan drug designation About 372,000 people are diagnosed with SCLC annually worldwide Rowan DunneJanuary 27, 2025
Medical and Pharmaceutical Deep learning AI model proves itself useful for CT imaging tumour analysis It was trained by examining over 1,500 CT scans Rowan DunneJanuary 23, 2025
Medical and Pharmaceutical bioAffinity Technologies secures Australian patent for ‘CyPath Lung’ spit test It will be issued within 3 months provided that there are no opposition filings made by third parties Rowan DunneJanuary 22, 2025